Clinical Analysis of PTEN, p53 and Her-2/neu Expressions in Thyroid Cancers

Abstract

Insights

Reduced PTEN protein expression and increased HER-2 protein expression are linked to thyroid cancer development. This study analyzed PTEN and HER-2 in thyroid tumors, finding significant correlations with cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The tumor suppressor gene PTEN (Phosphatase and Tensin homolog) is frequently altered in human cancers.
  • PTEN alterations are rare in sporadic thyroid cancers, necessitating further investigation into its role.
  • Understanding PTEN and HER-2/neu expression is crucial for thyroid cancer pathogenesis.

Purpose of the Study:

  • To investigate PTEN protein expression in thyroid cancer.
  • To examine the relationship between PTEN expression and clinical factors in thyroid cancer.
  • To analyze the correlation of PTEN expression with HER-2/neu and p53 in thyroid cancer.

Main Methods:

  • Immunohistochemical staining was performed on 62 thyroid cancer and 24 benign thyroid tumor specimens.
  • Monoclonal antibodies against PTEN, HER-2/neu, and p53 were used.
  • Statistical analysis was conducted to evaluate the results.

Main Results:

  • PTEN under-expression was significantly more frequent in thyroid cancers (29%) compared to benign tumors (4.2%).
  • PTEN expression reduction was not significantly related to tumor size, age, lymph node metastasis, or p53 status.
  • A significant relationship was found between PTEN under-expression and HER-2 over-expression (p=0.001) in thyroid cancers. HER-2 over-expression was noted in 83.8% of thyroid cancers versus 16.7% of benign tumors.

Conclusions:

  • Under-expression of PTEN protein and over-expression of HER-2 protein may contribute to thyroid cancer development.
  • These molecular alterations suggest potential roles in thyroid carcinogenesis.
  • Further research into PTEN and HER-2 pathways could inform therapeutic strategies for thyroid cancer.